1,128 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fulvestrant Non-Small Cell Lung Carcinoma	IDEAYA Biosciences	P2	CCC (52)
Gilteritinib Non-Small Cell Lung Carcinoma	Astellas Pharma Global Development, Inc.	P1/2	CCC (52)
hlx26 Non-Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (52)
hs-20117 Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P2/3	CCC (52)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody; Conjugated To Auristatin E Non-Small Cell Lung Carcinoma	Shanghai Miracogen Inc.	P2	CCC (52)
Inupadenant Non-Small Cell Lung Carcinoma	iTeos Therapeutics	P2	CCC (52)
Iza-Bren Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P2/3	CCC (52)
js212 for Non-Small Cell Lung Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (52)
Luvometinib Non-Small Cell Lung Carcinoma	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P2	CCC (52)
Nadravaleucel Non-Small Cell Lung Carcinoma	BOE Technology Group Co., Ltd.	P2	CCC (52)
Neratinib Non-Small Cell Lung Carcinoma	Convalife (Shanghai) Co., Ltd.	P2	CCC (52)
Olvimulogene Nanivacirepvec Non-Small Cell Lung Carcinoma	Genelux Corporation	P2	CCC (52)
Pank-003 Cell Non-Small Cell Lung Carcinoma	Shenzhen Celconta Life Science Co., Ltd.	P2	CCC (52)
pm8002 Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (52)
Ponsegromab Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (52)
Quaratusugene Ozeplasmid Non-Small Cell Lung Carcinoma	Genprex, Inc.	P1/2	CCC (52)
Rifaldazine Non-Small Cell Lung Carcinoma	TYK Medicines, Inc	P1	CCC (52)
Rosuvastatin Non-Small Cell Lung Carcinoma	Bayer	P1	CCC (52)
Sagramostim Non-Small Cell Lung Carcinoma	Vestre Viken Hospital Trust	P2	CCC (52)
Sarilumab Non-Small Cell Lung Carcinoma	Regeneron Pharmaceuticals	P2	CCC (52)
Setidegrasib Non-Small Cell Lung Carcinoma	Astellas Pharma Global Development, Inc.	P3	CCC (52)
Shr-8068 Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P2/3	CCC (52)
skb571 for Non-Small Cell Lung Carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P2	CCC (52)
sms001 Non-Small Cell Lung Carcinoma	ToLymph Inc.	P2	CCC (52)
Tagitanlimab Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P2	CCC (52)
T-Dxd Non-Small Cell Lung Carcinoma	Iambic Therapeutics, Inc	P1/2	CCC (52)
Ubamatamab Non-Small Cell Lung Carcinoma	Regeneron Pharmaceuticals	P2	CCC (52)
Visugromab Non-Small Cell Lung Carcinoma	CatalYm GmbH	P2	CCC (52)
YH 001 Non-Small Cell Lung Carcinoma	Eucure (Beijing) Biopharma Co., Ltd	P2	CCC (52)
Zenocutuzumab Non-Small Cell Lung Carcinoma	Partner Therapeutics, Inc.	P2	CCC (52)
Adbelimumab Non-Small Cell Lung Carcinoma	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (51)
Atirmociclib Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (51)
b1962 Non-Small Cell Lung Carcinoma	Tasly Biopharmaceuticals Co., Ltd.	P2	CCC (51)
bat3306 Non-Small Cell Lung Carcinoma	Bio-Thera Solutions	P3	CCC (51)
Bevacizumab Biosimilar - Shanghai Henlius Biotech Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P2	CCC (51)
Cetuximab Sarotalocan Non-Small Cell Lung Carcinoma	Roswell Park Cancer Institute	P2	CCC (51)
Deb-Bace Non-Small Cell Lung Carcinoma	Gang Wu	P2	CCC (51)
Diclofenac Non-Small Cell Lung Carcinoma	Emory University	P2	CCC (51)
hb1801 Non-Small Cell Lung Carcinoma	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P2	CCC (51)
js207 Non-Small Cell Lung Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (51)
js212 Non-Small Cell Lung Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (51)
Jskn033 Non-Small Cell Lung Carcinoma	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P2	CCC (51)
Nelistotug (Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd96 (T Cell Activation Increased Late Expression, Tactile, T-Cell Surface Protein Tactile)], Homo Sapiens Monoclonal Antibody) Non-Small Cell Lung Carcinoma	GlaxoSmithKline	P2	CCC (51)
Neoantigen-Loaded Dc Vaccine Non-Small Cell Lung Carcinoma	The First Affiliated Hospital of Nanchang University	P2	CCC (51)
pf-07248144 Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (51)
shr2554 Non-Small Cell Lung Carcinoma	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (51)
SX682 Non-Small Cell Lung Carcinoma	University of Washington	P2	CCC (51)
Tedopi Non-Small Cell Lung Carcinoma	Fondazione Ricerca Traslazionale	P2	CCC (51)
Teonanacatl Non-Small Cell Lung Carcinoma	Alan Davis	P2	CCC (51)
Tifcemalimab Non-Small Cell Lung Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (51)

Showing 301 to 350 of 1,125 assets

PreviousPage 7 of 23Next